PCDHA10: A Potential Drug Target for Cancer (G56139)

Target Name: PCDHA10

NCBI ID: G56139

PCDHA10

PCDHA10: A Potential Drug Target for Cancer

PCDHA10, also known as PCDHA10 variant 1, is a protein that is expressed in various tissues throughout the body. It is a member of the PCDH gene family, which is known for its role in the development and maintenance of tissues during development and throughout life.

One of the unique aspects of PCDHA10 is its role in the development and progression of cancer. Studies have shown that PCDHA10 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancers. It has also been shown to play a role in the development of metastasis.

In addition to its role in cancer development, PCDHA10 has also been shown to be a potential drug target. Studies have shown that inhibiting PCDHA10 has the potential to treat various types of cancer, including breast, ovarian, and prostate cancers. This is because PCDHA10 is involved in many cellular processes that are necessary for cancer growth and progression, including cell division, angiogenesis (the formation of new blood vessels), and the regulation of cell signaling pathways.

One of the reasons that PCDHA10 is thought to be a good drug target is its involvement in the PI3K/AKT signaling pathway. This pathway is a well-established target for many types of cancer, including breast, ovarian, and prostate cancers. Activation of the PI3K/AKT signaling pathway has been shown to promote the growth and survival of cancer cells, and inhibition of this pathway has been shown to have therapeutic benefits.

Another potential mechanism by which PCDHA10 may be a drug target is its role in cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs, and it is a critical aspect of many cellular processes, including embryonic development and tissue repair. Studies have shown that PCDHA10 is involved in the regulation of cell adhesion, and that alterations in this process have been implicated in many types of cancer.

In addition to its role in cell adhesion and the PI3K/AKT signaling pathway, PCDHA10 has also been shown to be involved in many other cellular processes that are important for cancer growth and progression. For example, it has been shown to play a role in the regulation of cell cycle progression, the production of cell surface antigens (such as CD47), and the regulation of cell apoptosis (programmed cell death).

Given its involvement in so many cellular processes that are important for cancer growth and progression, it is not surprising that PCDHA10 has been identified as a potential drug target. Many studies have shown that inhibiting PCDHA10 has the potential to treat various types of cancer, including breast, ovarian, and prostate cancers. However, more research is needed to fully understand the role of PCDHA10 as a drug target and to develop effective treatments for cancer.

Protein Name: Protocadherin Alpha 10

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHA10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHA10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets